DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Motavizumab

Motavizumab

  • Pdf

    Pdf

  • Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens

    Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens

  • Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: a Free Assay Disguised As Total

    Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: a Free Assay Disguised As Total

  • Structural Basis for Nonneutralizing Antibody Competition at Antigenic

    Structural Basis for Nonneutralizing Antibody Competition at Antigenic

  • Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: a Noninferiority Trial

    Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: a Noninferiority Trial

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

  • List Item Synagis-H-C-257-P46-0036 : EPAR

    List Item Synagis-H-C-257-P46-0036 : EPAR

  • Michigan Care Improvement Registry HL7 2.5.1 Specification Guide for Query by Parameter (QBP)

    Michigan Care Improvement Registry HL7 2.5.1 Specification Guide for Query by Parameter (QBP)

  • Pediatric Pharmacy Practice Making a Difference When and Where It Counts!

    Pediatric Pharmacy Practice Making a Difference When and Where It Counts!

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

  • (RSV F) to Elicit High Neutralizing Antibody Titers

    (RSV F) to Elicit High Neutralizing Antibody Titers

  • Preferred Product Characteristics of Monoclonal Antibodies for Passive

    Preferred Product Characteristics of Monoclonal Antibodies for Passive

  • 2006 Drug Trend Report

    2006 Drug Trend Report

  • Cvx List.Pdf

    Cvx List.Pdf

  • (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

    (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep

  • VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1- Exposed Infants

    VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1- Exposed Infants

  • Wo 2009/055030 A2

    Wo 2009/055030 A2

  • International Nonproprietary Names (INN) for Biological and Biotechnological Substances

    International Nonproprietary Names (INN) for Biological and Biotechnological Substances

Top View
  • © Copyright 2018 Dennis Ryan Goulet
  • A Randomized Controlled Trial of Motavizumab Versus Palivizumab
  • Who Drug Information
  • Structure Basis of Neutralization by a Novel Site II/IV Antibody Against Respiratory Syncytial Virus Fusion Protein
  • Supplementary Tables and Figures Section 1. Distribution of CDR-H3
  • Combination AZD7442 Rapidly Advances Into Ph
  • Does Respiratory Syncytial Virus Lower Respiratory Illness in Early Life Cause
  • Drug Monographs
  • Astrazeneca Scales Back Motavizumab
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
  • Gold Standard Drug Monographs
  • Therapeutic Neutralizing Monoclonal Antibodies: Report of a Summit Sponsored by Operation Warp Speed and the National Institutes of Health
  • The South East London Red, Amber, Grey (RAG) Medicines List for Adults - Updated January 2020
  • Clinicalkey Drug Monographs
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0293.086 A1 MESSMER Et Al
  • (INN) for Biological and Biotechnological Substances
  • Passive Immunoprophylaxis Against Respiratory Syncytial Virus in Children: Where Are We Now?
  • Standouts Melanoma Drug Yervoy, with Seemingly Better Tolerability


© 2024 Docslib.org    Feedback